Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Copyright © WAPE. All rights reserved.

Loading news article.

EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability | WAPE

Newsbenzinga

EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability

Oct 13, 2026, 07:45 ET · Published

Article summary

Scienture Holdings reports Q3 revenue of $1.22M, up 256% QoQ, driven by Arbli growth and the launch of Rezenopy.

An excerpt from the original article.

Related companies

Scienture Holdings, Inc. Common StockSCNXView stock

Analyzed by WAPE AI.

Preparing English content…

Comments —

Comment

Loading comments…